How COVID-19 has impacted Triall
Triall: Bringing web 3.0 to medical research by delivering blockchain-enabled software solutions for clinical trials
Introduce
A new type of software platform aims to transform the predictive analytics, machine learning, and medical development industry the unique Blockchain technology is used. And smart multiday in clinical trials. Their mission is to reduce the costs of drugs and speed up market medicines. There is a need for a logon that will bring you the latest in science and technology.
The basic premise of a clean tax is to reduce medicines for those who need a logon. Find out more about clinical trial information, clinical trial pros, and more tips and tricks. Cost-effective for pharmaceutical companies researching new drugs for the market. By developing a range of critical applications targeting specific key pain points and bottlenecks in clinical trials, Triall aims to revolutionize the way pharmaceutical companies collaborate in clinical trials.
About Triall
Triall is laying the groundwork for tomorrow’s digital playing field in clinical trials. They bring Web 3.0 to medical research by developing a digital ecosystem of blockchain-integrated software solutions. Triall’s blockchain infrastructure makes medical data tamper-resistant and enables secure and efficient connections between the many isolated systems and parties involved in clinical research.
Triall’s mission is to accelerate the introduction of safe and affordable vaccines and therapeutics into society by streamlining clinical trial operations.
The Triall ecosystem, a multi-sided platform for clinical research
The growth of the eClinical market and the need for unifying the eClinical solutions currently available on the market provide Triall with ample opportunities. Triall’s blockchain-integrated back-end infrastructure will open up the possibility of connecting previously isolated eClinical solutions in a multi-sided platform. Using Triall’s APIs, existing eClinical providers get an easy entry to the blockchain functionalities within Triall’s infrastructure while also having the possibility to connect with Triall solutions and other third-party connected solutions.
Curious to learn more about our vision? We published a 3-part series on blockchain in clinical trials in which we dive into the unique opportunities offered by blockchain technology in tackling some of the persisting issues in today’s clinical trials.
A Tokenized Light at the End of the Tunnel
The Triall project takes a research-backed ecosystem approach that is tailored to the critical needs faced by clinical trial professionals today. The ecosystem is developed with the principles of the cryptocurrency industry in mind, incentivizing a diverse community of project investors and clinical trial stakeholders to create and capture value through tokenization. COVID-19 has gained global attention and awareness of healthcare systems and has demonstrated key areas for improvement. As we emerge from the global pandemic, Triall builds a strong community of synergic partners, advisors, investors, and stakeholders that pioneer the bridges between healthcare and crypto domains.
Token allocation
Triall will offer 52% of the total TRL token supply to the community through its Initial Token Offering (ITO) and through the Triall Community Fund. This ITO serves to distribute early access to the Triall ecosystem and will support in funding its development. TRL tokens are issued using the ERC-20 standard on Ethereum and are available for anyone meeting our legal requirements.
Let’s dive into the key figures of our ITO. Please note that figures depicted between parentheses indicate percentage of the total TRL token supply.
- The total TRL token supply at ITO will be 175 million.
- A total of 91 million TRL (52%) will be distributed to the community, of which 31,5 million (18%) will be allocated to the Pre-sale, 42 million (24%) to the Treasury, and 17,5 million (10%) to the Triall Community Fund.
- Any unsold tokens from the Pre-sale will be burned.
- The Pre-sale price of 1 TRL will be $ 0,125 in the Private Pre-sale round (5%), $ 0,20 in the Retail Pre-sale round (2,5%), and $ 0,20* in the Late Bird Pre-sale round (7,5%).
- The listing price of 1 TRL will be $ 0,25.
- The hard cap will be $ 1.093.750 in the Private Pre-sale round, $ 875.000 in the Retail Pre-sale round, and $ 2.625.000** in the Late Bird Pre-sale round.
- All token allocation pools are bound to a vesting schedule.
- The market cap*** at the time of our token generation event (TGE) will be $ 916.563 (2,10%).
The role of Triall
The COVID-19 pandemic has exemplified the value of clinical trials to society. Clinical trials are a crucial part of the development of new medicines as they evaluate the safety and efficacy of new vaccines and therapeutics before these enter the market. This process typically takes 10 years and requires the collaboration of many different stakeholders such as pharma companies, hospitals, patients, and various specialized service providers. The data collected in these clinical trials utlimately allows market regulators such as the FDA to assess whether a new medicine can be introduced on the market. At the start of the pandemic, many clinical trials were temporarily put on hold as hospitals were overwhelmed by the influx of COVID-19 patients. Fortunately, the clinical trial industry proved to be very versatile, quickly adjusting to this new operating environment, and within no-time many clinical trial projects were back on track. In the next sections, we’ll explain how the pandemic has left a lasting impact on our industry and how we as a company navigated through this crisis. Lastly, Triall will also take a peak into the future. Keep on reading for more.
At Triall, thye respond directly to this need by leveraging blockchain to promote the integrity and auditability of clinical trials as well as tackle data fragmentation by enabling secure data exchange between stakeholders and their systems. Together with our partners, advisors, and growing community, we’re developing the world’s first blockchain-enabled digital ecosystem for clinical trials. Underpinning this ecosystem is our main utility token $TRL which provides access to all Triall solutions while also enabling P2P compensation, governance, and community engagement. All of this is geared towards our mission: accelerating the introduction of new vaccines and therapeutics into society to ensuring that society’s emerging medical needs can continue to be met.
Conclusion
As the importance of medicine in the society cannot be eroded away, the benefits of Triall cannot be missed. The speed in the delivery of new medicines to market, and the driving down of price is an opportunity to embrace. Don’t Miss!!!
Visit the website: https://www.triall.io
Twitter: https://twitter.com/triallofficial
Telegram: https://t.me/triallcommunity
About the author: ciaraluisu